UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2016

OR 

o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 333-148546

HEMCARE HEALTH SERVICES INC.

(FORMERLY NSU RESOURCES INC)

(Exact name of registrant as specified in its charter)

Nevada	20-8248213
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)
4830 W. Kennedy Blvd., Suite 600, Tampa, FL 33609 (Address of principal executive offices, including zip code.) (844) 4-HEMCARE, (844) 4-436-2273
(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting Company. See the definitions of “large accelerated filed,” “accelerated filer” and “smaller reporting Company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	¨	Smaller reporting Company	x
(Do not check if a smaller reporting Company)

Indicate by check mark whether the registrant is a shell Company (as defined in Rule 12b-2 of the Exchange Act. Yes o No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

As of December 14, 2016 the issuer had 273,332,211 shares of common stock issued and 272,952,211 shares of common stock outstanding.

FORWARD-LOOKING STATEMENTS

This Form 10-Q for the quarterly period ended June 30, 2016 contains forward-looking statements that involve risks and uncertainties. Forward-looking statements in this document include, among others, statements regarding our capital needs, business plans and expectations. Such forward-looking statements involve assumptions, risks and uncertainties regarding, among others, the success of our business plan, availability of funds, government regulations, operating costs, our ability to achieve significant revenues, our business model and products and other factors. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict”, “potential” or “continue”, the negative of such terms or other comparable terminology. In evaluating these statements, you should consider various factors, including the assumptions, risks and uncertainties set forth in reports and other documents we have filed with or furnished to the SEC. These factors or any of them may cause our actual results to differ materially from any forward-looking statement made in this document. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding future events, our actual results will likely vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested herein. The forward-looking statements in this document are made as of the date of this document and we do not intend or undertake to update any of the forward-looking statements to conform these statements to actual results, except as required by applicable law, including the securities laws of the United States.

 

2

TABLE OF CONTENTS

FORM 10-Q

QUARTER ENDED JUNE 30, 2016

		Page
PART I - FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited)	4
	Unaudited Balance Sheets as of June 30, 2016 and December 31, 2015	4
	Unaudited Statements of Operations for the three and six months ended June 30, 2016 and 2015	5
	Unaudited Statements of Cash Flows for the six months ended June 30, 2016 and 2015	6
	Notes to unaudited financial statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	11
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	13
Item 4.	Controls and Procedures	13
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	14
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	14
Item 3.	Defaults Upon Senior Securities	14
Item 4.	Submission of Matters to a Vote of Security Holders	14
Item 5.	Other Information	14
Item 6.	Exhibits	15

 

3

Item 1: Financial Statements

HEMCARE HEALTH SERVICES INC.
Balance Sheets (Unaudited)
	June 30, 2016			December 31, 2015
ASSETS
Current assets
Cash	$	17		$	20,334
Prepaid expenses		1,134			2,630
Total current assets		1,151			22,964
Total assets	$	1,151		$	22,964
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities
Accounts payable and accrued liabilities	$	98,571		$	86,896
Preferred stock dividends payable		23,857			19,000
Related party payables		37,249			37,249
Current notes payables		350,000			350,000
Convertible notes payable, net of discounts $18,496 and $12,835		12,204			385
Related party convertible notes payable, net of discounts $989 and $10,249		1,635			3,865
Total current liabilities		523,516			497,395
Stockholders' deficit
Series A convertible preferred stock, $1.00 par value; 5,000,000 shares authorized, 81,170 shares issued and outstanding		81,170			81,170
Common stock, $0.001 par value; 275,000,000 shares authorized; 142,162,211 issued; 141,782,211 outstanding		142,162			142,162
Additional paid in capital		2,573,165			2,556,665
Other comprehensive income		24			24
Treasury stock, 380,000 shares		(100	)		(100	)
Accumulated deficit		(3,318,786	)		(3,254,352	)
Total stockholders' deficit		(522,365	)		(474,431	)
Total liabilities and stockholders' deficit	$	1,151		$	22,964
See accompanying notes to unaudited financial statements.

 

4

HEMCARE HEALTH SERVICES INC.
Statements of Operations (unaudited)
	Three months ended June 30,						Six months ended June 30,
	2016			2015			2016			2015
Revenue	$	-		$	-		$	-		$	-
Operating expenses
General and administrative		2,922			700			7,158			4,909
Professional fees		11,468			355,123			15,888			362,832
Total operating expenses		14,390			355,823			23,046			367,741
Other income (expense)
Other income		-			-			-			-
Interest expense		(18,392	)		-			(36,531	)		(3,546	)
Excess cost of prepaid royalties over value		-			(67,235	)		-			(67,235	)
Total other income (expense)		(18,392	)		(67,235	)		(36,531	)		(70,781	)
Net loss	$	(32,782	)	$	(423,058	)	$	(59,577	)	$	(438,522	)
Preferred stock dividends declared		(2,428	)		-			(4,857	)		-
Net loss attributable to common shareholders	$	(35,210	)	$	(423,058	)	$	(64,434	)	$	(438,522	)
Basic and diluted loss per common share	$	(0.00	)	$	(0.01	)	$	(0.00	)	$	(0.01	)
Weighted average shares outstanding		141,782,211			62,498,967			141,782,211			32,981,470
See accompanying notes to unaudited financial statements.

 

5

HEMCARE HEALTH SERVICES INC.
Statements of Cash Flows (unaudited)
	Six months ended June 30,
	2016			2015
Cash flows from operating activities
Net loss from operations	$	(59,577	)	$	(438,522	)
Adjustments to reconcile net loss to net cash used in operating activities
Excess cost of prepaid royalties over value		-			67,235
Note payable entered into for professional fees		-			350,000
Amortization of debt discounts		20,089			-
Changes in operating assets and liabilities
Prepaid expenses		1,496			-
Accounts payable and accrued liabilities		11,675			8,432
Net cash used in operating activities		(26,317	)		(12,855	)
Net cash used in investing activities		-			-
Cash flows from financing activities
Repayments of related party convertible note payable		(8,000	)		-
Proceeds from convertible notes payable		16,500			-
Repayments of convertible note payable		(2,500	)		-
Net cash used in financing activities		6,000			-
Net change in cash		(20,317	)		(12,855	)
Cash at beginning of period		20,334			-
Cash at end of period	$	17		$	(12,855	)
Supplemental cash flow information:
Cash paid for interest	$	-		$	-
Cash paid for income taxes	$	-		$	-
Supplemental disclosure of non-cash financing activity:
Preferred stock dividends payable	$	4,857		$	-
See accompanying notes to unaudited financial statements.

 

6

HEMCARE HEALTH SERVICES INC.

Notes to Unaudited Financial Statements

June 30, 2016

Note 1 - Basis of Presentation

The accompanying unaudited interim financial statements of Hemcare Health Services Inc. (formerly NSU Resources, Inc.) (collectively referred to herein as “Hemcare Health Services”, “Hemcare”, or the “Company”), have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission, and should be read in conjunction with the audited financial statements for the period ended December 31, 2015 and notes thereto contained in the Company’s Form 10-K filed with the SEC. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosure contained in the audited financial statements for fiscal 2015 as reported in the form 10-K have been omitted.

Note 2 - Going Concern

The Company had an accumulated deficit of $3,318,786 and a working capital deficit of $522,365 as of June 30, 2016. These matters raise substantial doubt about the Company’s ability to continue as a going concern. Continuation of the Company’s existence depends upon its ability to obtain additional capital. Management’s plans in regards to this matter include raising additional equity financing and borrowing funds under a private credit facility and/or other credit sources. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Note 3 - Significant Accounting Policies

Use of Estimates

The preparation of financial statements, in conformity with generally accepted accounting principles in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

Cash Equivalents

The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents.

Prior Period Conformity

The Company has reclassified balances in the prior period financial statements for conformity with the current period for comparison purposes.

Income Taxes

The Company accounts for income taxes under the asset and liability method, where deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

At June 30, 2016, there were no uncertain tax positions that require accrual.

7

HEMCARE HEALTH SERVICES INC.

Notes to Unaudited Financial Statements

June 30, 2016

Note 3 - Significant Accounting Policies (continued)

Net Income (Loss) Per Share

Basic loss per share is computed by dividing net income, or loss, by the weighted average number of shares of common stock outstanding for the period. Diluted earnings (loss) per share is computed by dividing net income, or loss, by the weighted average number of shares of common stock outstanding for the period.

Because the Company reported net losses for the three and six months ended June 30, 2016 and 2015, basic and diluted loss per share was the same as any outstanding instruments would have an anti-dilutive effect.

Recently Issued Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.

Note 4 - Related Party Transactions

No salaries were paid to directors or executives during the period ended June 30, 2016.

On August 8, 2015, the Company entered into a convertible note payable for $15,784 in exchange for the related party payable incurred from expenses paid on behalf of the Company. The note carries interest at a rate of 6% per annum, is due on August 24, 2016 and may be converted into common stock of the Company at the option of the noteholder at a rate of $.01 per share. The beneficial conversion feature in the note created a debt discount of $15,784 of which $5,535 was recognized during the year ended December 31, 2015 leaving an unamortized discount of $10,249 as of December 31, 2015 that will be recognized over the remaining life of the note. There was $10,634 of principal plus accrued interest totaling $360 due as of December 31, 2015. During the six months ended June 30, 2016, the Company made total repayments of $8,000 leaving a total principal balance of $2,634 and accrued interest of $526 due as of June 30, 2016. The remaining unamortized debt discount as of June 30, 2016 was $999.

Note 5 – Stockholders’ Equity

Series A Convertible Preferred Stock

As discussed in the 8-K filed with the SEC on June 29, 2014, during the year ended December 31, 2014, the Company amended its articles of incorporation to designate the previously authorized series A preferred stock to series A convertible preferred stock. The preferred series A 12% convertible shares have a par value of $1, entitle holder to one vote and accrue dividends at 12% per year, paid quarterly. At the option of the holder, the stock can be converted into shares of the Company's common stock. The number of shares to be issued will be determined by dividing the amount of the Series A shares being converted by $0.001.

During year ended December 31, 2015, the Company issued 100,000 shares of series A convertible preferred stock in exchange for a prepayment of royalties and purchase of 40 complete Ultroid Hemorrhoids management systems and accessories with a deemed value of $0 due to the undeterminable nature of the true future usable value to the Company. The Company also accepted the conversion notices from certain series A convertible preferred shareholders to convert a total of 138,830 shares of series A preferred stock to 138,830,000 shares of $0.001 par value common stock.

The excess of the value of the preferred shares issued in excess of the value of the prepaid royalties has been expensed as a financing cost.

There were 81,170 shares of series A convertible preferred stock issued and outstanding as of June 30, 2016 and December 31, 2015. Additionally, the Company had accrued dividends payable on series A convertible preferred stock totaling $23,857 and $19,000 and $0 at June 30, 2016 and December 31, 2015.

 

8

HEMCARE HEALTH SERVICES INC.

Notes to Unaudited Financial Statements

June 30, 2016

Note 5 – Stockholders’ Equity (continued)

Common Stock

On March 2, 2015, the Company effected a 1:50 reverse stock split. The effects of the reverse split are shown retroactively in these financial statements.

The authorized common stock of the Company consists of 275,000,000 shares and carries a par value of $0.001. During the year ended December 31, 2014, the Company bought back 380,000 post-split shares of common stock into treasury from a former officer for $100. The shares are being carried as treasury shares as reflected on the balance sheet.

During the year ended December 31, 2015, the Company rescinded 730,000 common shares previously issued pursuant to certain agreements. The Company determined the holders did not have legal right to the shares as issued. During the year ended December 31, 2015, the Company issued 138,830,000 common shares from the conversion of 138,830 shares of Series A Preferred Stock. During the year ended December 31, 2015, the Company issued 900,000 shares of common stock for total cash proceeds of $45,000 and 26,211 shares to account for rounding in our 1:50 stock split as previously discussed.

There were 142,162,211 common shares issued and 141,782,211 outstanding (post-split) at June 30, 2016 and December 31, 2015, respectively.

Note 6 – Notes Payable

During the year ended December 31, 2015, the Company entered into a note payable with an unrelated party as a settlement for payment of consulting services provided valued at $350,000. The note carries interest of 9% compounded annually and is due on November 19, 2016. There was $350,000 of principal and $35,211 and $19,504 of accrued interest due as of June 30, 2016 and December 31, 2015. Accrued interest payable is included in “accounts payable and accrued liabilities” on the balance sheet.

9

HEMCARE HEALTH SERVICES INC.

Notes to Unaudited Financial Statements

June 30, 2016

Note 7 – Convertible Notes Payable

During the year ended December 31, 2015, the Company entered into a convertible note payable with an unrelated party resulting in net cash proceeds to the Company totaling $19,700. The note is convertible into common stock of the Company at the option of the noteholder at a rate of $0.01 per share. The Company measured the value of the beneficial conversion feature of the note and recorded a discount equal to the face value of the note on the date of issuance. The discount will be recognized ratably over the life of the note through the due date as shown below. 

During the six months ended June 30, 2016, the Company entered into a convertible note payable with an unrelated party resulting in net cash proceeds to the Company totaling $16,500. The note is convertible into common stock of the Company at the option of the noteholder at a rate of $0.01 per share. The Company measured the value of the beneficial conversion feature of the note and recorded a discount equal to the face value of the note on the date of issuance. The discount will be recognized ratably over the life of the note through the due date as shown below.

A summary of the outstanding convertible notes payable as of June 30, 2016 follows:

	Due Date	Principal		Discount			Net Value
Noteholder 1	9/1/2016	$	14,200	$	(3,261	)	$	10,939
Noteholder 1	6/2/2017		16,500		(15,235	)		1,265
Total		$	30,700	$	(18,496	)	$	12,204

Note 8 – Commitments and Contingencies

As discussed in Note 5, the Company previously issued a total of 100,000 shares of series A convertible preferred stock in exchange for a prepayment of royalties and 40 complete Ultroid systems. Additionally, as discussed in Note 7, the Company entered into two separate convertible notes payable with an unrelated party. These transactions were not approved by unanimous board consent through the Company’s normal approval procedures. As such, the Company may challenge the validity of these agreements after additional review of the relevant details.

Note 9 - Subsequent Events

On August 26, 2016, the Company entered into a settlement agreement with a certain noteholder whereby the Company issued 50,000 shares of Series A Convertible Preferred Stock as repayment of $50,000 of the outstanding principal and accrued interest balance. The shares are convertible at the option of the holder to common stock at a rate of $0.001 per share.

On August 28, 2016, the Company accepted the conversion of a total of 131,170 shares of Series A Convertible Preferred Stock to 131,170,000 shares of Common Stock of the Company.

10

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operation.Shareholders’ Equity

Plan of Operations

During the second quarter of 2014, the Company exited the Rare Earth Elements business. As part of this exit, the Company assigned the exclusive license issued from 1776729 Ontario Corporation, a related party, for rare earth extraction and carbon credit technologies to its former officer for $100, thus terminating the Company's license in the technologies. Additionally, a full and mutual release was signed by the Company and Great Rock Development Corp. pertaining to the rare earth extraction technology use as described in the Company’s Form 8K filed on April 29, 2013.

On June 29, 2014 the Company was granted the perpetual exclusive rights to the use of Optimum Performance (a proprietary formulation of a highly potent all-in-one daily feed supplement for the Horse industry. In consideration for the assignment of these rights, the Company will pay a gross sales royalty of 1.5% on future sales and agreed to pre-pay royalties by the issuance of 120,000 Preferred Series A 12% Convertible shares to 2412151 Ontario Limited.

During the year ended December 31, 2015, the Company shifted its business focus to hemorrhoid medical procedures and entered into a license agreement to open hemorrhoid treatment centers and promote the Ultroid Hemorrhoid System globally. In consideration for the transfer of these rights to the Company, it issued 100,000 shares of series A preferred convertible stock.

Limited Operating History; Need for Additional Capital

There is no historical financial information about us upon which to base an evaluation of our performance. Our assets and business have not yet generated substantial or recurring revenues. We cannot guarantee we will be successful in our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources and possible cost overruns due to price and cost increases in services.

We will require additional financing to cover costs that we expect to incur over the next twelve months. We believe that debt financing will not be an alternative for funding our operations as we do not have tangible assets to secure any debt financing. We anticipate that additional funding will be in the form of equity financing from the sale of our common stock or other securities. However, we cannot provide any assurance that we will be able to raise sufficient funding from the sale of our common stock to fund our plan of operations. In the absence of such financing, we will not be able to continue and our business plan will fail.

Results of Operations

Revenues

Revenues during the three and six months ended June 30, 2016 and 2014 were $0. The timing of generating revenues from the sale or the Ultroid Hemorrhoid System is presently undeterminable.

Operating Expenses

Total operating expenses were $23,046 and $367,741 during the six months ended June 30, 2016 and 2015, and $14,390 and $355,823 during the three months ended June 30, 2016 and 2015, respectively. The decrease in the current period is the result of timing of professional fees incurred associated with our public filings in 2016 when compared to 2015.

Liquidity and Capital Resources

As of June 30, 2016 we had $17 of cash, total current assets of $1,151 and current liabilities of $523,516 creating a working capital deficit of $522,365. Current liabilities as of June 30, 2016 consisted of $98,571 of accounts payable and accrued liabilities, $37,249 of related party payables, $23,857 of dividends payable, notes payable of $350,000 and convertible notes payable net of discounts totaling $13,839.

11

Cash Used in Operating Activities

Net cash used in operating activities was $26,317 during the six months ended June 30, 2016 compared to $12,855 used for the same period in 2015. The increase in cash used in operating activities is from an increase in operating expenses incurred during the six months ended June 30, 2016 when compared to the six months ended June 30, 2015.

Cash from Financing Activities

We have funded our business to date primarily from loans from directors or other related parties. There are no assurances that we will be able to achieve further sales of our common stock or any other form of additional financing. If we are unable to achieve the financing necessary to continue our plan of operations, then we will not be able to continue our operations and our business will fail.

Going Concern

Through June 30, 2016, management has devoted most of its activities to developing a market for its products and services. We have recently executed an agreement whereby the Company was transferred the rights to distribute and sell a unique hemorrhoid treatment product. We have yet to generate revenues from the sale of this product, have limited cash on hand and have a working capital deficit of $522,365 which raises substantial doubt for the entity to be able to continue as a going concern.

Future Financing

We anticipate continuing to rely on equity sales of our common stock in order to continue to fund our business operations. Issuances of additional shares will result in dilution to our existing shareholders. There is no assurance that we will achieve any additional sales of our equity securities or arrange for debt or other financing to fund our planned operations.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

Lawsuits

To management’s knowledge there is no pending, or threatened lawsuit against the Company

12

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a smaller reporting company, we are not required to provide the information required by this item.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) that are designed to ensure that information required to be disclosed by us in reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to management, including our Chief Executive Officer (as our chief executive officer and chief financial officer), to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. As of the end of the period covered by this report, and under the supervision and with the participation of management, including our Chief Executive Officer, who is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act, conducted an evaluation of the effectiveness of the design and operation of these disclosure controls and procedures. Based on this evaluation and subject to the foregoing, our Chief Executive Officer concluded that these controls are not effective considering the level and nature of the Company’s operations and the number and types of transactions concluded by the Company.

Changes in Internal Control Over Financial Reporting

During the period covered by this report management of the Company was expanded to include more than one individual. As such, there were significant changes in our internal controls during the period. For example, for the time being and until the operations of the company make this impractical all financial transactions involving the Company, including all payments and all agreed upon incurrences of liabilities, require a signature from, or other approval from, the CEO or CFO of Hemcare Health Services. Notwithstanding these changes, as the company was previously a shell company owned and managed by one person, management has no reason to believe that the internal controls in place at that time were insufficient. Furthermore, management believes that until the operations of the Company progress to the point where tight control impedes smooth operations, it will be appropriate and sufficient (from the perspective of internal controls over financial reporting) if approval of the CEO and CFO is required for transactions that are or are reasonably likely to require disclosure in the financial statements.

13

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

We are not presently a party to any legal proceedings and, to our knowledge, no such proceedings are threatened or pending.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Description of Registrant’s Securities to be Registered

The authorized capital stock of our Company consists of 275,000,000 shares of common stock, par value $0.001 per share, of which there are currently 273,332,211 issued and 272,952,211 outstanding, and 5,000,000 shares of series A convertible preferred stock authorized of which there are 0 shares issued and outstanding.

All outstanding shares of common stock are of the same class and have equal rights and attributes. The holders of common stock are entitled to one vote per share on all matters submitted to a vote of stockholders of the Company. All stockholders are entitled to share equally in dividends, if any, as may be declared from time to time by the sole director out of funds legally available. In the event of liquidation, the holders of common stock are entitled to share ratably in all assets remaining after payment of all liabilities. The stockholders do not have cumulative or preemptive rights.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Submission of Matters to a Vote of Security Holders.

None

Item 5. Other Information.

None.

14

 

Item 6. Exhibits.

The following exhibits are attached hereto:

Exhibit No.	Description of Exhibit
31.1	Certification of Principal Executive Officer pursuant to Rule 13a-15(e) and 15d-15(e), promulgated under the Securities and Exchange Act of 1934, as amended, filed herewith.
31.2	Certification of Principal Accounting Officer pursuant to Rule 13a-15(e) and 15d-15(e), promulgated under the Securities and Exchange Act of 1934, as amended, filed herewith.
32.1	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed herewith

15

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Hemcare Health Services Inc.

By:	/s/ John Wilkes	By:	/s/ John Wilkes
	John Wilkes		John Wilkes
	President and Chief Executive Officer		Chief Financial Officer, Secretary and Treasurer
	(Principal Executive Officer)		(Principal Financial Officer)
	December 14, 2016		December 14, 2016

16